Thales Completes the Acquisition of Imperva, Creating a Global Leader in Cybersecurity
4.12.2023 09:00:00 EET | Business Wire | Press release
Thales (Euronext Paris: HO) announces today that it has completed the acquisition of Imperva, earlier than expected (previously foreseen at the beginning of 2024). This is a key milestone for Thales, creating a global leader in cybersecurity, with more than 5,800 cybersecurity experts across 68 countries and €2.4bn in cybersecurity revenue expected in 2024, including civil and defence activities, with double-digit growth expected thereafter. This transaction will generate significant value creation for Thales’ shareholders in line with the targets communicated in July 2023, when announcing the acquisition. In addition, the profile of Thales’ Digital Identity and Security (DIS) activity will be significantly enhanced with new financial targets by 2027 (2024-2027 organic sales growth of +6 to +7% and 2027 EBIT margin at 16.5%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203476964/en/
©Thales
Patrice Caine, Chairman and Chief Executive Officer of Thales, said: “The acquisition of the US company Imperva is an important day for Thales, as it marks a new step in the expansion of our global cybersecurity capabilities for enterprises and governments around the world. We are very excited to welcome the Imperva teams to Thales. The combination of our entities' values and our joint commitment to a future of trust will create significant synergies, business opportunities and major market innovations. With ever-increasing cyber threats against business and government digital infrastructure, Thales is now uniquely positioned to help customers protect the heart of their digital ecosystem: applications, data and identities.”
Data-Centric Security spanning across Applications, Data and Identities
Together, Thales and Imperva will help customers address cybersecurity challenges that have increased rapidly in frequency, severity, and complexity, with the most comprehensive solutions for the broadest range of application, data security, and identity use cases. These three market segments combined are forecasted to grow significantly in the coming years. According to analysts’ forecast, worldwide end-user spending is projected to total around $20 billion in 2024.
With the addition of Imperva, Thales’ expanded cybersecurity portfolio now offers a highly complementary combination of solutions to help customers secure applications, data and identities across their entire digital ecosystem:
- Application Security: Unified protection for every application and API in the cloud, on-premises, or in a hybrid model. The market leading product suite includes Web Application Firewall (WAF), Distributed Denial of Service attack (DDoS) Protection, Advanced Bot Protection, Application Programming Interface (API) Security, a developer-friendly Content Delivery Network (CDN), and Runtime Application Self-Protection (RASP).
- Data Security: Protection and control of access to sensitive data anywhere whether at rest, in motion or in use. The product suite includes the CipherTrust Data Security Platform, Imperva Data Security Fabric, as well as the Luna and payShield Hardware Security Modules, often used as the root of trust for cryptographic operations.
- Identity & Access Management: seamless, secure and trusted access to applications and digital services for customers, employees and partners. The product suite includes the OneWelcome Identity Platform and SafeNet Trusted Access.
“As a long-standing partner of both Thales and Imperva, we at Exclusive Networks are delighted with the combination of two companies that we know and value,” said Jesper Trolle, CEO Exclusive Networks. “This acquisition marks a key step in Thales' ambition to become a global leader in cybersecurity, reinforcing its strength in data security and expanding into the buoyant application security market. With this new combined value proposition, Thales will be uniquely positioned to offer even more innovative and effective solutions to address the growing security and compliance challenges faced by organisations around the world.”
This is Thales’ ninth acquisition in the digital security area over the last nine years, and the second largest in the Group's history after Gemalto, world leader in digital security. After the completed acquisitions of Tesserent , the leading player in cybersecurity in Australia, S21sec & Excellium, two major players in cybersecurity consulting, integration and managed services in Europe, and OneWelcome, a European leader in Customer Identity and Access Management, the integration of Imperva within Thales will position the Group’s cybersecurity business as one of the top 5 global leaders in cybersecurity.
Thales in North America
With 6,200 employees1 and €2.4 billion revenues2 in North America in 2022, and approximately 50% of the free float shares held by U.S. shareholders, Thales already has a strong presence in the region. The acquisition of Imperva increases Thales’ digital security workforce in North America by almost a third.
Each year, Thales invests €4 billion in R&D, of which €1 billion is self-financed3. The Group is fully committed to supporting Imperva’s customers and augmenting its solutions through accelerated innovations. As an innovator, Thales has a total of 20,000 patents in its portfolio, more than 50% of these involve key technologies related to AI, generative artificial intelligence, cybersecurity, big data, the cloud, augmented reality and quantum technologies.
|
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees4 in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Thales Group
Security
https://cpl.thalesgroup.com/about-us/thales-imperva
_____________
1
Including GTS employees
2
Without GTS revenues
3
Group-level data
4
Excluding the Transport business, which is currently being divested
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231203476964/en/
Contact information
Head of Media Relations
Cédric Leurquin
+33 (0)6 31 01 53 25
cedric.leurquin@thalesgroup.com
Thales, Media Relations
Security
Marion Bonnet
+33(0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
